Research & Development

Research & DevelopmenR&D Pipeline


       

 

Aiming to Commercialize Eye Disease Therapy through Korea’s 1st
Human Embryonic Stem Cell Clinical Trial

 

Macular Degeneration


    Vision loss due to degeneration of macular, a part of retina responsible
     for detailed vision and central vision
    Blindness and visual impairment in adults over age 50
     (Age-related Macular Degeneration)
    Juvenile macular degeneration due to gene mutation
     (Stargardt Macular Degeneration)
    Age onset decreased and number of patients increased due to
     population aging

 

hESC-derived RPE Manufacturing Process Scheme

CHA Biotech’s MA09-hRPE

    Phase I/IIa clinical trial for dry AMD ongoing
    Phase I clinical trial for SMD completed
    Announced world’s 1st hESC-derived RPE follow up safety trial results
     (Jun,2015)      

 
CEO Message
Vision
History
Overseas Corporations
Affiliated Companies
Business Overview
Cord Blood Banking Business
Bio Insurance Business
CHAUM Business(Non-medical)
IT Business
Other Businesses
CHA Biotech R&D Center
R&D Pipeline
Current Status of Clinical Trials
Patent Grants (Korea/Overseas)
Scientific Publications
Corporate Filings
Stock Information
IR Presentations